{
    "clinical_study": {
        "@rank": "46958", 
        "arm_group": {
            "arm_group_label": "GRID 18F-MISO", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To estimate the mean and standard deviation (SD) of the post-treatment decreases in the\n      interstitial fluid pressure and hypoxia-specific PET-scan signal from GRID-treated tumors in\n      patients with locally advanced squamous-cell carcinoma of the head and neck.\n\n      The possible effects of GRID radiotherapy on tumor oxygenation levels and interstitial fluid\n      pressure within the tumors will be measured by assessing the trend and statistical\n      significance of the difference in values for each condition obtained prior to and just after\n      GRID exposure in each subject enrolled in the study. We expect that there may be a trend for\n      increases in tumor oxygenation and decreases in interstitial fluid pressure which would\n      indicate that more accurately timed additional chemotherapy and radiation therapy would\n      improve overall patient outcomes."
        }, 
        "brief_title": "Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of the Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 80 years of age\n\n          -  Karnofsky performance status greater than 70 or ECOG \u2265 2\n\n          -  Cytological or histological documentation of squamous cell carcinoma of the head and\n             neck, including the tongue, with a minimum tumor size of 6cm in any dimension.\n\n          -  History of adequate hepatic function (endoscopic or percutaneous drainage as needed):\n\n             a. AST (SGOT) / ALT (SGPT) \u2264 5X institutional ULN\n\n          -  Chemotherapy naive\n\n          -  History of adequate renal and bone marrow function:\n\n               1. Leukocytes \u2265 3000/uL\n\n               2. ANC \u2265 1500/uL\n\n               3. Platelets \u2265 100000/UI\n\n               4. Serum Creatinine \u2264 2.0 mg/dL\n\n        Exclusion Criteria:\n\n          -  Women with a positive urine pregnancy test are excluded from this study; women of\n             childbearing potential (defined as those who have not undergone a hysterectomy or who\n             have not been postmenopausal for at least 24 consecutive months) must agree to\n             refrain from breast feeding and practice adequate contraception as specified in the\n             informed consent. Adequate contraception consists of oral contraceptive, implantable\n             contraceptives, injectable contraceptives, a double barrier method, or abstinence\n\n          -  Subjects with active infections such as pneumonia, or wound infections that would\n             preclude study procedures\n\n          -  Subjects with known presence of central nervous system or brain metastases\n\n          -  Subjects with prior radiotherapy to the head and neck region\n\n          -  Subjects will be excluded if deemed unable to comply with study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967927", 
            "org_study_id": "138725", 
            "secondary_id": "138725"
        }, 
        "intervention": {
            "arm_group_label": "GRID 18F-MISO", 
            "description": "A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).", 
            "intervention_name": "18F-MISO", 
            "intervention_type": "Drug", 
            "other_name": [
                "[18F]FMISO", 
                "[18F]FLUOROMISONIDAZOLE", 
                "1H-1-(3-[18F]-FLUORO-2-HYDROXY-PROPYL)-2-NITRO-IMIDAZOLE"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Fluoromisonidazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "carcinoma", 
            "cancer", 
            "head", 
            "neck", 
            "otolaryngology"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72120"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy", 
        "overall_official": {
            "affiliation": "University of Arkansas", 
            "last_name": "Robert J Griffin, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To estimate the mean and standard deviation of the decrease in interstitial fluid pressure in tumors within 72 hours after GRID treatment.", 
            "safety_issue": "No", 
            "time_frame": "within 72 hours after GRID treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967927"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Arkansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arkansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}